Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 0.85 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4696619 | 0.99 | AURKA (0.83) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL3880426 | 0.92 | AURKA (0.85) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL3885418 | 0.92 | AURKA (1.00) | AURKA | |
| SCHEMBL3894750 | 0.91 | AURKA (0.84) | AURKA | |
| Hydrochloric Acid SCHEMBL4695926 | 0.91 | AURKA (0.83) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL3885716 | 0.91 | AURKA (0.84) | AURKANTRK1INSRAURKB | |
| Hydrochloric Acid SCHEMBL4698082 | 0.91 | AURKA (0.82) | AURKA | |
| SCHEMBL3891858 | 0.90 | AURKA (0.82) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL3884212 | 0.90 | AURKA (0.82) | AURKA | |
| SCHEMBL3880899 | 0.88 | AURKA (0.78) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | claimed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | claimed |
| US-7485661-B2 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| EP-1534716-B1 | HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-04-23 | — | — | EP | disclosed |
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160874-A1 | Heterobicyclic pyrazole derivatives as kinase inhibitors | MAP2K2, MAP3K15, MAP3K5 | AURKA 239/4885NTRK1 1803/4885INSR 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.